Literature DB >> 11730839

Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA.

Marie P Piechocki1, Shari A Pilon, Wei-Zen Wei.   

Abstract

To establish standard methods for measuring anti-ErbB-2 antibody, a flow cytometric and an enzyme-linked immunosorbent assay (ELISA) were developed and compared. In the flow cytometric assay, the antibody was measured by binding to human breast cancer cell line SKBR3 and the result expressed as mean channel fluorescence (MCF). In ELISA, the antibody was measured by binding to a recombinant, secreted human ErbB-2 containing the N-terminal 505 amino acids of ErbB-2 fused to myc and His tags (secE2/myc/His or secE2) and the result expressed as O.D.(405). A mouse anti-human ErbB-2 mAb 9G6 was used as the standard. Using flow cytometry, MCF of 9G6 binding increased with linearity between 0.6 and 10 microg/ml. Using ELISA, O.D.(405) increased with linearity between 0.015 and 1 microg/ml, indicating greater sensitivity of ELISA. The titer of an immune mouse serum was determined to be 400 and 8000 with flow cytometric and ELISA assay, respectively, consistent with the assay sensitivity. Based on standard curves generated with 9G6, antibody concentration in the same serum sample was calculated to be approximately 230 microg/ml by ELISA and approximately 270 microg/ml by flow cytometry. Therefore, excellent concordance in antibody concentration was obtained with different assays using linear regression and properly diluted samples. This concordance was verified with multiple serum samples.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11730839     DOI: 10.1016/s0022-1759(01)00487-2

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  18 in total

1.  An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.

Authors:  Zachary C Hartman; Junping Wei; Takuya Osada; Oliver Glass; Gangjun Lei; Xiao-Yi Yang; Sharon Peplinski; Dong-Wan Kim; Wenle Xia; Neil Spector; Jeffrey Marks; William Barry; Amy Hobeika; Gayathri Devi; Andrea Amalfitano; Michael A Morse; H Kim Lyerly; Timothy M Clay
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.

Authors:  Richard F Jones; Joyce D Reyes; Heather M Gibson; Jennifer B Jacob; Ulka Vaishampayan; Stuart Ratner; Kang Chen; Wei-Zen Wei
Journal:  Cancer Immunol Immunother       Date:  2019-06-08       Impact factor: 6.968

3.  An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer.

Authors:  Michael A Morse; Amy C Hobeika; Takuya Osada; Peter Berglund; Bolyn Hubby; Sarah Negri; Donna Niedzwiecki; Gayathri R Devi; Bruce K Burnett; Timothy M Clay; Jonathan Smith; H Kim Lyerly
Journal:  J Clin Invest       Date:  2010-08-02       Impact factor: 14.808

Review 4.  The "A, B and C" of Her-2 DNA vaccine development.

Authors:  Wei-Zen Wei; Jennifer Jacob; Olga Radkevich-Brown; Paula Whittington; Yi-chi M Kong
Journal:  Cancer Immunol Immunother       Date:  2008-02-14       Impact factor: 6.968

5.  Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity.

Authors:  Jennifer B Jacob; Yi-chi M Kong; Ilke Nalbantoglu; Daniel P Snower; Wei-Zen Wei
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

6.  DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies.

Authors:  Paula J Whittington; Marie P Piechocki; Henry H Heng; Jennifer B Jacob; Richard F Jones; Jessica B Back; Wei-Zen Wei
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

7.  Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.

Authors:  Michael A Morse; Junping Wei; Zachary Hartman; Wenle Xia; Xiu-Rong Ren; Gangjun Lei; William T Barry; Takuya Osada; Amy C Hobeika; Sharon Peplinski; Haixiang Jiang; Gayathri R Devi; Wei Chen; Neil Spector; Andrea Amalfitano; H Kim Lyerly; Timothy M Clay
Journal:  Int J Cancer       Date:  2010-06-15       Impact factor: 7.396

8.  Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice.

Authors:  Guangwu Xu; Tameka Smith; Finn Grey; Ann B Hill
Journal:  Biochem Biophys Res Commun       Date:  2013-06-27       Impact factor: 3.575

9.  Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity.

Authors:  Paula J Whittington; Olga Radkevich-Brown; Jennifer B Jacob; Richard F Jones; Amy M Weise; Wei-Zen Wei
Journal:  Cancer Immunol Immunother       Date:  2008-10-03       Impact factor: 6.968

10.  Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice.

Authors:  Olga Radkevich-Brown; Jennifer Jacob; Michael Kershaw; Wei-Zen Wei
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.